PBMC Gene Expression Data for Peg-IFN-α Response in Chronic Hepatitis B

A clinical dataset from a prospective study of HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α for 48 weeks. The dataset likely contains mRNA expression levels of ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells, correlated with virological and serological response outcomes. It was authored by Hao Pang and last updated on 2026-04 -13.

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Assessing the diagnostic performance of gene expression biomarkers using ROC/AUC analysis.
• Modeling the association between dynamic changes in biomarker expression and HBsAg clearance.
• Identifying early therapeutic response indicators at weeks 12 and 24 of treatment.

Strengths

• Includes specific performance metrics for biomarkers, such as an AUC of 0.9230 for ADAR1 predicting VR at week 24.
• Based on a prospective clinical study with defined response groups (VR, NVR, SR, NSR) and a 48-week follow-up.
• Published under a CC-BY-4.0 license, allowing for open reuse and redistribution.

Limitations

• Row count and column-level documentation are unknown, requiring manual inspection after download.
• The dataset is very small at 25.7 KB, indicating limited scope and likely a small sample size.
• Data is provided in a DOCX format, which may require extraction and conversion for analysis.

Provenance

Source

figshare, authored by Hao Pang.

Collection Method

Data likely gathered from a prospective clinical trial involving real-time quantitative PCR measurements on patient PBMCs.

Time Range

Treatment and follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:10; freshness should be verified.

Geography

null